{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:41:37Z","timestamp":1794004897576,"version":"4.8.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature Nanotech"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/s41565-017-0043-5","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T06:38:31Z","timestamp":1517207911000},"page":"214-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":324,"title":["A modular platform for targeted RNAi therapeutics"],"prefix":"10.1038","volume":"13","author":[{"given":"Ranit","family":"Kedmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuphar","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Ramishetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Dammes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Hazan-Halevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limor","family":"Nahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Leviatan-Ben-Arye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Harlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Behlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Benhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"43_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2014.84","volume":"9","author":"JE Dahlman","year":"2014","unstructured":"Dahlman, J. E. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648\u2013655 (2014).","journal-title":"Nat. Nanotechnol."},{"key":"43_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nbt1223","volume":"24","author":"JO McNamara II","year":"2006","unstructured":"McNamara, J. O. II et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005\u20131015 (2006).","journal-title":"Nat. Biotechnol."},{"key":"43_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrg3978","volume":"16","author":"A Wittrup","year":"2015","unstructured":"Wittrup, A. & Lieberman, J. Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16, 543\u2013552 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"43_CR4","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","volume":"9","author":"S Ramishetti","year":"2015","unstructured":"Ramishetti, S. et al. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 9, 6706\u20136716 (2015).","journal-title":"ACS Nano"},{"key":"43_CR5","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1073\/pnas.1519273113","volume":"113","author":"S Weinstein","year":"2016","unstructured":"Weinstein, S. et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc. Natl Acad. Sci. USA 113, E16\u2013E22 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"43_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/mt.2015.175","volume":"24","author":"JA Katakowski","year":"2016","unstructured":"Katakowski, J. A. et al. Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses. Mol. Ther. 24, 146\u2013155 (2016).","journal-title":"Mol. Ther."},{"key":"43_CR7","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1073\/pnas.0608491104","volume":"104","author":"D Peer","year":"2007","unstructured":"Peer, D., Zhu, P., Carman, C. V., Lieberman, J. & Shimaoka, M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl Acad. Sci. USA 104, 4095\u20134100 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"43_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","volume":"23","author":"E Song","year":"2005","unstructured":"Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709\u2013717 (2005).","journal-title":"Nat. Biotechnol."},{"key":"43_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/hyb.1.1982.1.257","volume":"1","author":"TA Springer","year":"1982","unstructured":"Springer, T. A., Bhattacharya, A., Cardoza, J. T. & Sanchez-Madrid, F. Monoclonal antibodies specific for rat IgG1, IgG2a, and IgG2b subclasses, and kappa chain monotypic and allotypic determinants: reagents for use with rat monoclonal antibodies. Hybridoma 1, 257\u2013273 (1982).","journal-title":"Hybridoma"},{"key":"43_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/protein\/6.4.449","volume":"6","author":"ML Laukkanen","year":"1993","unstructured":"Laukkanen, M. L., Teeri, T. T. & Keinanen, K. Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. Protein Eng. 6, 449\u2013454 (1993).","journal-title":"Protein Eng."},{"key":"43_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0014-5793(96)01335-X","volume":"399","author":"J Kruif de","year":"1996","unstructured":"de Kruif, J., Storm, G., van Bloois, L. & Logtenberg, T. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett. 399, 232\u2013236 (1996).","journal-title":"FEBS Lett."},{"key":"43_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172\u2013176 (2010).","journal-title":"Nat. Biotechnol."},{"key":"43_CR13","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/nn506248s","volume":"9","author":"ZR Cohen","year":"2015","unstructured":"Cohen, Z. R. et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano. 9, 1581\u20131591 (2015).","journal-title":"ACS Nano."},{"key":"43_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/eji.1830250216","volume":"25","author":"S Tiisala","year":"1995","unstructured":"Tiisala, S., Paavonen, T. & Renkonen, R. Alpha E beta 7 and alpha 4 beta 7 integrins associated with intraepithelial and mucosal homing, are expressed on macrophages. Eur. J. Immunol. 25, 411\u2013417 (1995).","journal-title":"Eur. J. Immunol."},{"key":"43_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1126\/science.1149859","volume":"319","author":"D Peer","year":"2008","unstructured":"Peer, D., Park, E. J., Morishita, Y., Carman, C. V. & Shimaoka, M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627\u2013630 (2008).","journal-title":"Science"},{"key":"43_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.immuni.2012.08.026","volume":"37","author":"E Zigmond","year":"2012","unstructured":"Zigmond, E. et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37, 1076\u20131090 (2012).","journal-title":"Immunity"},{"key":"43_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nm.3189","volume":"19","author":"JR Grainger","year":"2013","unstructured":"Grainger, J. R. et al. Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection. Nat. Med. 19, 713\u2013721 (2013).","journal-title":"Nat. Med."},{"key":"43_CR18","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/protein\/7.12.1509","volume":"7","author":"I Benhar","year":"1994","unstructured":"Benhar, I. & Pastan, I. Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs Bl and B5 as single-chain immunotoxins. Protein Eng. 7, 1509\u20131515 (1994).","journal-title":"Protein Eng."},{"key":"43_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-62703-586-6_10","volume":"1060","author":"L Vaks","year":"2014","unstructured":"Vaks, L. & Benhar, I. Production of stabilized scFv antibody fragments in the E. coli bacterial cytoplasm. Methods Mol. Biol. 1060, 171\u2013184 (2014).","journal-title":"Methods Mol. Biol."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41565-017-0043-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-017-0043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-017-0043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:53:17Z","timestamp":1684605197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-017-0043-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["43"],"URL":"https:\/\/doi.org\/10.1038\/s41565-017-0043-5","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]},"assertion":[{"value":"8 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B. is an employee of Integrated DNA Technologies, Inc. J.L. is on the Scientific Advisory Board of Alnylam Pharmaceuticals. D.P. declares financial interests in Quiet Therapeutics. The rest of the authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}